The International Federation of Pharmaceutical Manufacturers and Associations and its members have committed to submitting the results of all industry-sponsored Phase III clinical trials for publication in scientific peer-reviewed journals. However, Germany’s health technology appraisal institute, IQWiG, said that the IFPMA’s bid to improve transparency does not go far enough to prevent publication bias...
Please login to read the full article.
